WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has extended the expiration of its warrants for twelve months to January 26, 2004.

Rockwell's Board of Directors approved the extension of the expiration date of the warrants for twelve months, expiring January 26, 2004. Rockwell warrants trade under the symbol RMTIW with an exercise price of $4.50 per Common Share. The warrants have a call feature and may be redeemed by the Company provided the bid price of the Common Shares has been at least $7.00 for 20 consecutive trading days ending on the third day prior to the date the notice of redemption is given.

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process that duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the patent approved Dri-Sate® Dry Acid Mixing System, Liquid Concentrate, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release including estimates of additional sales revenue expected to be generated under the new supply agreement constitute"forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(return to News Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, was selected as a "Future 50 of Greater Detroit Company for 2002.

Sponsored by BDO Siedman, LLP, the Detroit Regional Chamber, Raymond James & Associates and WWJ NewsRadio 950, the award was given to Rockwell in recognition of the Company's "outstanding contribution to Metropolitan Detroit through sales and employment growth".

The Detroit Regional Chamber's "Detroiter" magazine listed Rockwell in the "2002 Future 50 Winners" in its October 2002 issue.

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process that duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the patent approved Dri-Sate® Dry Acid Mixing System, Liquid Concentrate, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release including estimates of additional sales revenue expected to be generated under the new supply agreement constitute"forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(return to News Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, reported today that third quarter 2002 revenue was $2,882,853, an increase of 27.6% over the third quarter of 2001. Similarly, revenue for the first nine months of 2002 was $7,890,777, an increase of 18.1% over the first nine months of 2001. Rockwell's sales growth was primarily driven by growth in its dialysis concentrate product lines led by increases in sales of its acid concentrate product lines, including its proprietary Dri-Sate® Dry Acid Concentrate product line.

The Company reported a third quarter loss of ($182,852) as compared to a loss of ($459,844) in the third quarter of 2001. The Company reduced its loss by $277,000 primarily due to an increase in gross profit of $227,000 which was largely due to higher sales revenue and improved margins. Third quarter loss per share was ($.02) as compared to ($.07) in the third quarter of 2001 with operational improvements accounting for a gain of $.04 per share and the remainder attributable to an increase in the number of Common Shares outstanding.

The Company realized higher gross profit margins in the third quarter of 2002 with gross profit margins increasing to 14.4%, a 6.1 percentage point increase over the third quarter of 2001. Similarly, gross profit margins increased 4 percentage points over the second quarter of 2002. Margin improvements were the result of manufacturing efficiencies driven by increased sales volumes.

For the first nine months of 2002, the Company reported a loss of ($907,864) as compared to a loss of ($1,101,277) in the first nine months of 2001. Sales increased by 18.1% in the first three quarters of 2002 and partially offset the increase in ongoing operating costs related to the Company's expansion and upgrade of its manufacturing equipment in the second half of 2001 and first half of 2002. For the first three quarters of 2002, loss per share was ($.12) as compared to ($.19) in the first three quarters of 2001 with operational improvements accounting for a gain of $.03 per share and the remainder due to an increase in the average number of Common Shares outstanding.

Mr. Robert L. Chioini, Chairman, CEO and President of Rockwell stated, “We are pleased with our progress in the third quarter in growing the business and reducing the Company's operating losses. Gross profit margins improved as a result of reduced unit production costs from higher volume levels and improved distribution efficiencies gained from our new manufacturing facilities. We anticipate further improvements in both our sales revenue and gross profit margins in the fourth quarter. We think we should generate positive EBITDA in the fourth quarter thereby substantially reducing operating cash requirements.”

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process that duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the patent approved Dri-Sate® Dry Acid Mixing System, Liquid Concentrate, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release including estimates of additional sales revenue expected to be generated under the new supply agreement constitute"forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has signed a contract with National Nephrology Associates, Inc. (NNA) to supply NNA with arterial/venous fistula (AVF) needles with safety devices.

NNA, headquartered in Nashville, TN, is the sixth largest provider of dialysis services in the United States for patients suffering from chronic kidney failure. The company owns and operates kidney dialysis centers and home peritoneal dialysis programs in 15 states. NNA currently operates 85 outpatient dialysis facilities serving approximately 5,000 patients. The company also provides acute hemodialysis services to inpatients at approximately 53 hospitals.

The terms of the new supply contract call for NNA to purchase the Nipro SafeTouch Fistula Needle from Rockwell, via a distributor, for all NNA clinics. The SafeTouch AVF Needle is an arterial/venous fistula needle with a built-in safety device that helps prevent accidental needle-sticks. The contract term is for one year and is renewable thereafter upon mutual consent. The contract is anticipated to generate an additional $500,000 in annual sales revenue for Rockwell.

The Centers for Disease Control and Prevention estimate that healthcare workers sustain nearly 600,000 percutaneous injuries annually involving contaminated sharps. In response to both the continued concern over such exposures and the technological developments which can increase employee protection, Congress passed the Needlestick Safety and Prevention Act directing OSHA to revise the bloodborne pathogens standard to establish in greater detail requirements that employers identify and make use of effective and safer medical devices.

Mr. Rob Chioini, Chairman, CEO and President of Rockwell said, “We are pleased to further strengthen our business relationship with NNA. The revenue generated from this contract should help us get closer to profitability.”

In July of this year, Rockwell signed a dialysis concentrate supply contract with NNA which calls for NNA to purchase, on a national basis, Dri-Sate® Dry Acid Concentrate and bicarbonate powder from Rockwell over a three year term.

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process that duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the patent approved Dri-Sate® Dry Acid Mixing System, Liquid Concentrate, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release including estimates of additional sales revenue expected to be generated under the new supply agreement constitute"forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, reported today that second quarter 2002 revenue was $2,562,594, an increase of 17.9% over the second quarter of 2001. Similarly, revenue for the first six months of 2002 was $5,007,924, an increase of 13.2% over the first half of 2001. Rockwell's sales growth was primarily driven by growth in its dialysis concentrate product lines led by increases in its acid concentrate product lines, including its proprietary Dri-Sate Dry Acid Concentrate product line.

The Company reported a second quarter loss of ($378,798) as compared to a loss of ($355,747) in the second quarter of 2001. Second quarter loss per share was ($.05) as compared to ($.06) in the first quarter of 2001 with the decrease in loss per share due to an increase in the number of Common Shares outstanding.

During the second half of 2001, the Company expanded its production capacity by moving into and outfitting two new production facilities. Sales have increased and offset much of the ongoing operating costs related to the Company's capacity expansion. As a result, gross profit in the second quarter was $264,117 as compared to $259,385 in the second quarter of 2001. Cost increases include depreciation expense which increased $50,000 over the second quarter of 2001.

Also included in the second quarter results were product development and licensing costs related to water soluble dialysate iron which aggregated $30,000 for the quarter. In addition, in the second quarter of 2002, the Company took a one-time $50,000 non-cash charge on facility expenses pertaining to its move from its old manufacturing plant.

For the first six months of 2002, the Company reported a loss of ($725,012) as compared to a loss of ($641,433) in the first half of 2001. Sales increased by 13.9% in the first half of 2002 and partially offset the increase in ongoing operating costs related to the Company's expansion and upgrade of its manufacturing equipment. Loss per share was ($.10) as compared to ($.12) in the first half of 2001 with the improvement due to an increase in Common Shares outstanding.

Mr. Robert L. Chioini, Chairman, CEO and President of Rockwell stated, “During the quarter, we made substantial progress at selling the benefits of our patented Dri-Sate® Dry Acid Mixing System to key target customers. We believe this will translate into increased revenue in the quarters ahead. We have begun to realize lower incremental unit production costs and improvements in distribution efficiencies as a result of our equipment upgrade and our geographic expansion with our new Texas facility.”

He also said, “Second quarter saw continued progress at positioning the Company for future development. We have taken initial steps for regulatory approval of our Dialysate Iron, which we believe holds high potential in our marketplace. Dialysate Iron is an innovative product that we believe will be safer and more effective than current methods of delivering iron to dialysis patients. We also believe that Dialysate Iron has the potential to be less costly for the provider and will increase labor efficiency for clinic operators who are suffering from labor shortages.”

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process that duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the patent approved Dri-Sate® Dry Acid Mixing System, Liquid Concentrate, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release with respect to Rockwell's business and operations, particularly the statements of Mr. Chioini, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has signed a supply contract with National Nephrology Associates, Inc. (NNA).

NNA, headquartered in Nashville, TN, is the sixth largest provider of dialysis services in the United States for patients suffering from chronic kidney failure. The company owns and operates kidney dialysis centers and home peritoneal dialysis programs in 15 states. NNA currently operates 85 outpatient dialysis facilities serving approximately 5,000 patients. The company also provides acute hemodialysis services to inpatients at approximately 53 hospitals.

Rockwell currently services 53 NNA clinics under a previous supply contract. The general terms of the new supply contract call for NNA to purchase Dri-Sate® Dry Acid Concentrate and bicarbonate powder from Rockwell over a three year term, which is renewable upon mutual consent thereafter. The additional clinics in the new contract are anticipated to generate an additional $1 million in annual sales revenue for Rockwell.

Mr. Rob Chioini, Chairman, CEO and President of Rockwell said, “We are pleased to have the opportunity to expand and strengthen our supply relationship with NNA. This contract is a solid endorsement for the Dri-Sate® Dry Acid Mixing System and it's effectiveness in enabling the dialysis provider to reduce their cost per treatment and better utilize their facility space.”

Ms. Angela Newman, Assistant Vice President of Logistics for NNA stated, “NNA is pleased to have selected Rockwell as the supplier of dialysate for our clinics and acute units. Rockwell has demonstrated excellent customer and delivery service for current NNA clinics and we are confident that service will continue with the addition of other NNA facilities. The new agreement also streamlines the ordering and delivering process for NNA.”

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process that duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the patent approved Dri-Sate® Dry Acid Mixing System, Liquid Concentrate, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release including estimates of additional sales revenue expected to be generated under the new supply agreement constitute"forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis products manufacturer in the healthcare industry, announced today that it has engaged H. C. Wainwright & Co., Inc. to represent the Company as its investment banking firm.

H. C. Wainwright & Co., Inc., founded in 1868, is a research driven, national investment banking firm specializing in small and micro-cap growth companies. With offices in New York and Boston, H. C. Wainwright provides a full range of banking services to emerging growth companies.

Thomas E. Klema, Vice President and Chief Financial Officer stated, “We are pleased to have H.C. Wainwright as Rockwell's investment banker. We believe a high-quality investment banking firm specializing in the markets we operate in will help facilitate the next stage of the Company's development as well as add value for our shareholders.”

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process that duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the patent approved Dri-Sate® Dry Acid Mixing System, Liquid Concentrate, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release with respect to Rockwell's business and operations, particularly the statements of Mr. Chioini, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, reported today that first quarter 2002 revenue was $2,445,330, an increase of 8.7% over the first quarter of 2001. While the Company achieved sales growth across all of its product lines, unit volume growth in concentrate products represented the majority of the sales increase in the first quarter of 2002 as compared to the first quarter of 2001.

The Company reported a first quarter loss of ($346,200) as compared to a loss of ($285,700) in the first quarter of 2001. While revenue increased in the first quarter, ongoing operating costs related to the addition of production capacity in the second half of 2001 offset the impact of additional revenue. In addition, net interest expense of $30,000 in the first quarter of 2001 represented a $23,000 decrease in reported earnings compared to the first quarter of 2001. Despite the overall increase in net losses, net loss per share remained unchanged at ($.05) per share due to an increase in Common Shares outstanding.

Mr. Robert L. Chioini, Chairman, CEO and President of Rockwell stated, “The Company's results for the quarter were in line with our expectations. Our $1 million manufacturing equipment upgrade has been concluded in both production facilities and we now have the infrastructure in place to handle the growth that we expect to achieve in the quarters ahead.”

Mr. Chioini also said, “We achieved significant milestones during the first quarter of 2002. First, we signed exclusive agreements giving us the licensing rights to add a water-soluble iron supplement to our dialysate, which promises to offer significant improvement in the delivery of iron to dialysis patients. This is a very exciting development and holds high potential to capture a significant portion of the iron supplement market. Next, we were awarded patent approval on our proprietary Dri-Sate® Mixing System, which has generated substantial interest from dialysis providers looking to reduce their cost per treatment and better utilize their storage space. Lastly, we signed an exclusive agreement to distribute blood tubing in the U.S. and while it's still in its early stage of introduction it appears to be very promising.”

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process that duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers the patent approved Dri-Sate® Dry Acid Mixing System, Liquid Concentrate, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release with respect to Rockwell's business and operations, particularly the statements of Mr. Chioini, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect management's expectations and are based upon currently available information. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based upon reasonable assumptions. However, certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

NEW YORK/Business Wire/ -- The Wall Street Transcript has published an in-depth interview with Robert Chioini, Chairman and CEO of Rockwell Medical Technologies (Nasdaq:RMTI), in which he talks at length about the company's future.

The entire 4,000-word interview is available online at Rockwell's web site (interview text).

Chioini gives an overview of the company. “Rockwell is an innovative, US-based manufacturer and global distributor of high-quality hemodialysis products to the healthcare industry. The company supplies dialysis solutions and powders, blood tubing sets, fistula needles and other ancillary items needed for the dialysis treatment to be performed. The company currently operates two manufacturing plants located in Wixom, Michigan, and Grapevine, Texas.”

Chioini explains, “The hemodialysis market is a $1 billion market. With our current product line, we're addressing a market worth approximately $300 million annually. A new product, a proprietary product, that we've just recently licensed the worldwide rights to addresses a $350 million market in just the U.S., and is as high as $750 million globally.”

Looking forward, Chioini states, “We hope to be running at a profitable rate by the fourth quarter of this year. It's going to come down to how quickly we can bring on the business that we are currently securing; how quickly we can ramp up and start servicing those customers. There is no question that we'll be profitable. It's just a matter of how fast we can get there based on our book of business. So we're targeting the fourth quarter of this year, but if we experience any delays then it could be the first quarter of 2003.”

This interview is part of a 77-page Top-Performing Small Cap Stocks Issue available at http://www.twst.com/info/info540.htm  or by calling 212/952-7433.

The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call 800/246-7673.


(return to News Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc. a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, reported today that it received notification that the U.S. Patent and Trademark Office has allowed the patent application for its proprietary “Dri-Sate” brand dry dialysate system. This product is the focal point of Rockwell's proprietary technology for its dry acid concentrate product line.

The proprietary Dri-Sate™ Dry Acid Concentrate Mixing System provides an efficient way for dialysis providers to prepare and distribute dialysate solution needed for the dialysis treatment. The Dri-Sate™ Powder is a better alternative to pre-mixed liquid concentrates that are currently delivered in 55-gallon drums. It is packaged as a lightweight, condensed powder that is mixed on-site by the technician at the dialysis center. Once mixed, the product is equivalent to the acid provided to the dialysis center in liquid form. The Dri-Sate™ technology provides an automated system designed to work exclusively with the Dri-Sate™ Powder. It is compact, easy to operate and requires no additional plumbing installation. All that is required is an electrical outlet and a water source able to produce AAMI quality water, which all dialysis centers in the U.S. have. For the provider, the advantages for using the Dri-Sate™ Dry Acid Concentrate Mixing System include lower cost per treatment, increased storage space, fewer deliveries and greater flexibility in scheduling.

During the last decade, dialysis patient growth has shown a steady, predictable increase. Due to this growth, more and more patients continue to need dialysis treatment, which in turn has caused dialysis centers to put a premium on space. The Dri-Sate™ System enables the dialysis center to better utilize storage space that was previously restricted to liquid dialysate storage. By utilizing the Dri-Sate™ System, the dialysis center can store the equivalent of twenty-two 55-gallon drums, or 1210 gallons of solution, in the same single pallet space that would otherwise hold only four 55-gallon drums, or 220 gallons of liquid solution. This enables the dialysis center to potentially increase their storage space five-fold.

Mr. Rob Chioini, Chairman, CEO and President of Rockwell stated, “This patent is an important step in Rockwell's development. The success we continue to experience with the Dri-Sate™ Dry Acid Concentrate Mixing System is a result of its superior packaging and mixing technology, coupled with changing market conditions. We believe the concentrate market is in the beginning stages of a movement from liquid product to dry product and we will continue to be strong proponents of that change. The continual growth in the provider market has caused dialysis centers to search for ways to create more space and cut costs, and we believe that our Dri-Sate™ system not only solves these problems but is fast becoming a necessity.”

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process that duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers Dri-Sate™ Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.


(return to News Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc. a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, reported today that it has signed a supply contract to service St. Francis Medical Center's Renal Institute of the Pacific, which is part of the St. Francis Healthcare System of Hawaii.

The St. Francis Medical Center Renal Institute of the Pacific is the largest provider of dialysis services in Hawaii. The Company owns and operates 13 kidney dialysis centers serving approximately 1,100 dialysis patients suffering from chronic kidney failure.

The supply contract calls for St. Francis to purchase Dri-Sate™ Dry Acid Concentrate, liquid acid concentrate, bicarbonate powder and water filtration salts from Rockwell for a period of two years. Purchase volumes are anticipated to be approximately $1,000,000 during the term of the contract. At the end of the period, the contract can be renewed on an annual basis if both parties choose to do so.

According to a recent article published in the Honolulu Advertiser, about 1,500 people in Hawaii need dialysis treatments to stay alive. Also, in figures reported in February in a nationwide study by the National Kidney Foundation, another 200,000 people in Hawaii are at risk for kidney disease.

Mr. Rob Chioini, Chairman, CEO and President of Rockwell said, “We are pleased to have secured this supply contract. St. Francis is a high-quality, prestigious organization which treats the majority of the dialysis population in Hawaii. Rockwell's Dri-Sate™ is a superior dry acid product that was chosen by St. Francis and when coupled with our capability to manufacture and ship our complete product line from our Grapevine, Texas facility it allowed us to secure this concentrate business in Hawaii.”

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process that duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers Dri-Sate™ Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.


(return to News Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc. a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, reported today that its fourth quarter 2001 revenue was $2,334,000 and 8.7% higher than the fourth quarter of 2000. Fourth quarter revenue was the highest in the Company's history. Fourth quarter loss per share was ($.07) on a loss of ($478,000) which included a loss on disposition of equipment and relocation expenses that aggregated $82,000.

Sales for 2001 were $9,015,500 an increase of 20.9% over 2000, reflecting substantial growth in the Company's Dri-Sate Dry Acid Concentrate product line and overall dialysis concentrate product sales. The Company's operating loss was ($1,579,100) in 2001 as compared to ($1,016,800) in 2000. Loss per share for 2001 was ($.26) as compared to a loss per share of ($.21) in 2000 with the 2001 loss per share reduced by ($.06) due to an increase in the average number of shares outstanding.

During 2001, the Company undertook several initiatives to position it for future growth and profitability with the objective to provide the Company with sufficient productive capacity to achieve a profitable level of operations and to provide the Company with a proprietary product line. As a result of these initiatives, the Company incurred substantial additional costs in 2001 and its losses increased despite substantial growth in revenue.

The Company opened two new manufacturing facilities during 2001 that provided it with an increase in productive capacity and after obtaining equipment financing from GE Healthcare Financial Services, the Company added new and more efficient manufacturing equipment in the fourth quarter of 2001. However, the Company incurred substantial additional costs during the start-up phase of these two new facilities that aggregated over $600,000 and, in addition, when coupled with the loss on disposition of manufacturing equipment of $49,000, which was replaced by more productive equipment, represented the increase in the Company's operating loss in 2001 as compared to 2000.

On January 15, 2002, the Company announced that it has signed global licensing agreements for the inclusion of water soluble iron in its dialysate products. During Phase II clinical trials, Ferric Pyrophosphate was well tolerated by patients and proved to be effective at iron maintenance therapy without serious side effects noted with intravenous iron. The Company is required to obtain FDA approval to add iron to its dialysate and is currently working with the FDA on the scope and duration of Phase III clinical trials for Ferric Pyrophosphate. The Company believes that upon FDA approval iron maintenance therapy via dialysate will provide the Company with a proprietary product line.

Mr. Robert L. Chioini, Chairman, CEO, and President of Rockwell Medical Technologies, Inc. said, “We are pleased with our overall development efforts in 2001 in terms of both new product development with water soluble iron and market acceptance of our Dri-Sate and other product lines. We think Rockwell is poised to lead the migration of the provider market to dry products and away from drums. We are very excited about the prospects for Ferric Pyrophosphate as a significant improvement in iron maintenance therapy that we think will benefit patient outcomes and deliver operating efficiencies to providers both of which we believe will be compelling reasons for dialysis providers to switch to Rockwell.”

He also said, “We were disappointed at the increase in our operating loss in 2001 which was largely due to the added costs associated with the delay in getting the plants up and functional which resulted in slowing the pace of new business development from what we had anticipated. Earlier in the year, with just our old plant operating, we were continually pushing up against capacity constraints. However, that is no longer a concern now that we have the new plants up and running with substantially more productive equipment. We can now efficiently handle the new business we anticipate in the future,” stated Mr. Chioini.

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items including blood tubing. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc. a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has entered into an exclusive distribution agreement with Al-Mak Flower, Inc. for the sale and distribution of its Dri-Sate Dry Acid Concentrate Mixing System and its Bicarbonate Powder Concentrate in Macedonia.

The agreement calls for Al-Mak Flower, Inc. to be the exclusive sales agent and distributor for Rockwell Medical Technologies, Inc. in Macedonia for a period of three years. According to the agreement, Al-Mak Flower, Inc. will purchase minimum amounts of Rockwell's Dri-Sate Dry Acid Concentrate and Bicarbonate Powder Concentrate over the next 36 months. Purchase volumes are anticipated to be a minimum of $1 million during the term of the contract.

Mr. Robert L. Chioini, Chairman, CEO and President of Rockwell Medical Technologies, Inc., stated, “We are pleased to have Al-Mak Flower represent us in Macedonia. They are a high-caliber distributor who we anticipate securing additional distribution agreements through. We continue to see increased demand for Rockwell's dry concentrate product line outside of the U.S. and we expect to increase our international market presence going forward.”

Rockwell recently reported that it signed exclusive, worldwide, proprietary licensing agreements to market water-soluble iron through its dialysate. The Company believes that this innovation will represent a major advancement in the treatment of anemia in hemodialysis patients.

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Its Dri-Sate Dry Acid Concentrate provides substantial distribution synergies and operating efficiencies over traditional concentrate delivery in large drums of liquid. Its gamma-irradiated SteriLyte™ Liquid Bicarbonate Product Line provides extended shelf life and safety giving its customers an added degree of security. In January, Rockwell introduced a full line of high-quality blood tubing manufactured by Nipro Medical Corporation.

Hemodialysis is a process that duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(return to News Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc. a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, reported today that it has signed separate licensing agreements that give the Company exclusive, worldwide proprietary rights to manufacture, market and distribute a water-soluble iron supplement via the Company's dialysate.

Rockwell Medical Technologies, Inc. has entered into global licensing agreements, with both Ash Medical Systems, Inc. and Charak, LLC, that grant the Company the exclusive, worldwide rights to manufacture, market and distribute liquid and dry dialysate compositions containing water-soluble iron to be administered to both hemodialysis and peritoneal dialysis patients with renal failure.

Ash Medical Systems, Inc., based in Indiana, was co-founded by Nephrologist Dr. Stephen Ash who serves as the Chairman and Director of Research and Development. Charak, LLC, based in Ann Arbor, MI, was founded by Nephrologist Dr. Ajay Gupta who serves as the President and CEO.

Rockwell has licensed all patents, issued and pending, from both Ash Medical Systems, Inc. and Charak, LLC relating to the pharmaceutical composition, methods of use and delivery for all iron compounds, and specifically ferric pyrophosphate, to a dialysis patient. Based on results from FDA approved Phase II clinical studies, using dialysate as the delivery mechanism in hemodialysis patients, ferric pyrophosphate decreases the need for intravenous iron (IV iron) by 80% and consequently reduces the risks associated with the toxic effects of IV iron such as hypotension and anaphylactoid reactions, which can be life threatening. Unlike the IV iron, ferric pyrophosphate does not require processing by the liver and thereby eliminates the liver toxicity. It is effective in treating patients who are not able to release iron from storage sites due to a co-existent inflammatory state. Phase II clinical studies also showed that ferric pyrophosphate is well tolerated by patients without any short-term or long-term side effects. Most importantly, it maintains a constant state of iron balance thereby facilitating the hematopoietic effects of erythropoietin (EPOGEN), without overloading the tissues with iron and thereby mitigating oxidative injury. Released pyrophosphate is also an anti-oxidant, which reduces the negative impact of oxidative stress that occurs to the patient during dialysis.

Iron administration via dialysate is ideally suited for hemodialysis and peritoneal dialysis patients, and also those receiving hemodialysis at home who currently must travel to a hospital on a regular basis to receive IV iron. Furthermore, iron delivery via the dialysate eliminates nursing and pharmaceutical administration costs associated with IV iron administration.

Iron deficiency is very common among hemodialysis patients due to the administration of a drug manufactured by Amgen, Inc. (Nasdaq: AMGN), called EPOGEN (Epoetin alfa), that helps the body make red blood cells but also increases the body's need for iron, and due to the loss of blood that the dialysis patient experiences during treatment. Currently, a dialysis patient can receive iron orally, which is not very effective due to stomach problems, nausea and poor patient compliance, or intravenously, whereas iron is absorbed into the liver and is slowly released into the bloodstream losing much of its potency, and which can also cause serious adverse reactions. IV iron is the most prevalent form of iron administration currently used in dialysis and is manufactured by both American Regent Laboratories, Inc. and Watson Pharmaceuticals, Inc. (NYSE: WPI).

Rockwell estimates that the U.S. dialysis market for IV iron supplements represents greater than $350,000,000 annually. Worldwide it estimates that there are more than 1 million dialysis patients. The Company estimates that the global market potential for iron supplementation is more than double the U.S. potential representing approximately $750,000,000 annually.

Mr. Rob Chioini, Chairman, CEO and President of Rockwell said, “We are extremely pleased to have secured these exclusive, proprietary licensing rights. Dr. Gupta and Dr. Ash are experienced and well respected nephrologists within the renal community, and both have a passion for their work. This product will benefit both the dialysis patient and the dialysis provider. Dialysis patients need iron and based on clinical work, ferric pyrophosphate administered via dialysate is a safer, more effective and less costly method to deliver the needed iron to the dialysis patient.” Mr. Chioini further stated, “Adding ferric pyrophosphate to our acidified concentrate product line will give us a proprietary product and should put us in a strong position to increase market share in the dialysis concentrate market. This development, coupled with our Dri-Sate Dry Acid Concentrate and our recent exclusive blood tubing contract, gives us the ability to offer innovative, high-quality, proprietary pr oducts that not only lower the cost-per-treatment for the dialysis provider but that also improve the quality of patient care every dialysis provider can offer.”

Dr. Ajay Gupta, President of Charak, LLC stated, “Administration of ferric pyrophosphate via dialysate is a major advancement in the treatment of anemia in hemodialysis patients. It is the first demonstration that a simple iron salt can be delivered safely and effectively directly into the blood stream. It has potential to overcome functional iron deficiency, a hallmark of kidney failure, and thereby overcome resistance to EPOGEN action. Compared with the polymeric iron complexes delivered intravenously it has potential to reduce liver iron accumulation and liver injury, reduce oxidative stress and the associated vascular disease that predisposes heart attacks, strokes and gangrene and reduce vascular calcification.”

Dr. Stephen Ash, Chairman and Director of R&D of Ash Medical Systems, Inc. said, “The cost, effort and risk of IV iron is a problem to every dialysis unit in the country. The safe and effective administration of iron salts through dialysate should very quickly become the most desirable dialysate for the great majority of dialysis patients worldwide.”

Rockwell also recently reported that it signed an exclusive, multi-year contract with Nipro Medical Corporation (based in Osaka, Japan) to market and distribute hemodialysis blood tubing sets in the United States, which is a market estimated to generate more than $150 million annually, and that revenues increased 25.8% on sales of $6,681,000 for the first nine months of 2001.

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(return to News Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc. a leading, innovative hemodialysis concentrate manufacturer in the healthcare industry, announced today that it has signed an exclusive, multi-year contract with Nipro Medical Corporation to market and distribute hemodialysis blood tubing sets in the United States. Nipro, based in Osaka, Japan, is a leading global manufacturer of medical products with annual revenue of $1.2 billion.

Under the terms of the contract, Rockwell has the exclusive rights to sell Nipro's blood tubing sets to dialysis clinics and/or other distributors throughout the United States. The contract covers an initial period of five years and then can be extended.

Blood tubing sets are used during the dialysis treatment to transport the patient's blood as it is being cleaned. Currently, the blood tubing market is estimated to generate more than $150 million annually in the United States. Rob Chioini, Chairman, CEO and President of Rockwell, said, “We are very excited to be partnered with such a high-quality manufacturer like Nipro. Blood tubing is a product that goes hand-in-hand with concentrate and most dialysis clinics prefer to receive their ancillary products from their concentrate supplier.” Mr. Chioini also stated, “This is another important building block in our strategic plan. It should enable us to double our annual sales revenue just from supplying our current base of customers.”

Mike Rothe, Vice President, Sales of Nipro, said, “Nipro Medical Corporation is very pleased to have Rockwell as our blood tubing partner in the United States. Rockwell is an aggressive, growing company and because it manufactures dialysis concentrate and controls its distribution by using it's own trucks, we believe Rockwell has a significant strategic advantage in penetrating the blood tubing market.”

Rockwell recently reported revenues increased 25.8% on sales of $6,681,000 for the first nine months of 2001.

For more information on Nipro Medical visit their website at www.nipro.com.

Rockwell Medical Technologies, Inc., is an innovative leader in manufacturing, marketing and delivering high-quality dialysis solutions, powders and ancillary products to hemodialysis providers. Hemodialysis is a process which duplicates kidney function for patients whose kidneys have failed to function properly and suffer from end-stage renal disease (ESRD). There are an estimated 350,000 dialysis patients in the United States and the incidence of ESRD has increased 6-8% on average each year over the last decade. Rockwell offers Dri-Sate Dry Acid, Liquid Acid, SteriLyte™ Liquid Bicarbonate, Powder Bicarbonate and a wide range of ancillary dialysis items. Rockwell's products are used to cleanse the ESRD patient's blood and replace nutrients in the bloodstream.

This press release contains forward-looking statements with respect to Rockwell's business and operations. Management of Rockwell believes the expectations reflected in the forward-looking statements made in this press release are based on reasonable assumptions. Certain factors could occur that might cause actual results to vary. These include, but are not limited to, general economic conditions, economic conditions in the hemodialysis industry, competitive factors and other factors discussed in Rockwell's reports filed with the Securities and Exchange Commission. The forward-looking statements should be considered in light of these risks and uncertainties.

(Return to Archive Index)